Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED®
The agreement maintains key therapies within Kedrion’s U.S. immunodeficiency and auto immune disorders portfolio while reinforcing broad, reliable access for people living with serious and chronic immune-mediated disorders FORT LEE, N.J., August 18, 2026 – Kedrion Biopharma, a global biopharmaceutical company specializing in therapies for rare and serious diseases, today announced an extension to their relationship with Grifols under which Kedrion sells GAMMAKED® [Immune Globulin Injection (Human) 10% Caprylate/Chromatography Purified], an intravenous immunoglobulin (IVIG) therapy, in the United States to support patients living with serious and chronic conditions. The agreement
Kedrion Launches QIVIGY® in the U.S. with Nationwide Distribution
Kedrion has activated a robust nationwide U.S. distribution network to support the commercial availability of QIVIGY, its FDA approved 10% Intravenous Immunoglobulin (IVIG) therapy. Kedrion’s distribution model is designed to provide broad access across specialty pharmacies, infusion centers, hospitals, and other sites of care nationwide, ensuring consistent supply and scalable reach as demand for IVIG
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
First patient enrolled in KIDCARES10
Kedrion Biopharma Pediatric Primary Immunodeficiency Study
Kedrion Biopharma Phase III Trial, CARES10, achieves important milestone
Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases.